Five-year relative survival rates according to the year of diagnosis and the patients' age at diagnosis. Survival rates have increased over the past 35 years in all patient age groups, a trend attributed to the effect of novel agents such as thalidomide, bortezomib, and lenalidomide; however, significant increases in survival have only been observed in patients aged < 65 years at initial diagnosis.³